Defender Pharmaceuticals
Defender Pharmaceuticals is a privately held life sciences company based in St. Louis, MO, focused on developing innovative therapies to offer patients a sense of security and strength. The company aims to address challenging and potentially life-threatening conditions through novel science, leveraging the expertise of its team and partnerships with established institutions. Their work includes collaborations with the Department of Defense, NASA, and the Department of Veterans Affairs to improve health outcomes for both civilian and military populations.
Defender Pharmaceuticals
12935 N Outer Forty Rd, Suite #212, St. Louis, MO 63141
What We Do
DPI-386 is an intranasal scopolamine gel developed for the prevention of nausea and vomiting induced by motion. It is designed to offer rapid absorption and fast-acting relief through an innovative intranasal delivery system.
Application Area
Show More (1)Battlefield Resuscitation
Psychological and Cognitive Health and Performance
Digital Health Technologies
Routes of Administration
Services
Key People
President and Chief Executive Officer, Director
Acting Chief Financial Officer
Chief Operating Officer
Chief Commercial Officer
General Counsel and Chief Compliance Officer
Founder and Executive Chairman
News & Updates
An article discussing Defender Pharmaceuticals' funding and its efforts to gain approval for its lead drug candidate.
The FDA has accepted Defender Pharmaceuticals' New Drug Application for intranasally administered scopolamine gel (DPI-386 Nasal Gel), granting it priority review status at the request of the U.S. Navy. The PDUFA action date is set for January 26th, 2024.
Defender Pharmaceuticals has entered into an exclusive license agreement with the U.S. Army Medical Materiel Development Activity to develop and commercialize products for treating tropical diseases.
Defender Pharmaceuticals has initiated two Phase 2 clinical studies in collaboration with NASA to investigate DPI-386's ability to mitigate G-transition induced motion sickness and enhance sensorimotor performance.
Defender Pharmaceuticals received a Complete Response Letter from the FDA regarding its New Drug Application for intranasal scopolamine (DPI-386) for the prevention of nausea and vomiting induced by motion in adults. The company plans to address the issues raised in the letter and remains confident in the safety and efficacy of its product.
Defender Pharmaceuticals announced positive results from its pivotal Phase III clinical trial of DPI-386 Nasal Gel, demonstrating its effectiveness in preventing nausea and vomiting induced by motion. The trial showed significant results compared to placebo, marking an important milestone for the company.